By Denny Jacob

Regeneron Pharmaceuticals on Thursday said a U.S. Supreme Court opinion affirms a lower court opinion that held Amgen's asserted U.S. PCSK9 patent claims were invalid.

Biotechnology company Regeneron said the Supreme Court's opinion ends a nearly decade-long patent dispute related to its PCSK9 inhibitor, Praluent.

"We're gratified that the Supreme Court has affirmed the position we have held for nearly ten years that Amgen's PCSK9 patents were overly broad and inconsistent with established case law," said Executive Vice President Joseph LaRosa.

According to an Amgen spokeswoman, the company is disappointed by the ruling, but "will continue to fight for patent laws and policies that provide meaningful patent protection needed to foster breakthrough innovation."

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

May 18, 2023 12:54 ET (16:54 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Amgen.
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Amgen.